Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities
Open Access
- 1 January 2013
- journal article
- research article
- Published by Manuscript Technomedia LLP in Pharmacognosy Research
- Vol. 5 (4) , 241-246
Abstract
Context: To date, many findings reveal that most of the modern drugs have the ability to interact with herbal drugs. Aims: This study was conducted to determine the inhibitory effects of mitragynine on cytochrome P450 2C9, 2D6 and 3A4 activities. Methods and Material: The in vitro study was conducted using a high-throughput luminescence assay. Statistical Analysis: Statistical analysis was conducted using one-way ANOVA and Dunnett's test with P < 0.05 vs. control. The IC 50 values were calculated using the GraphPad Prism® 5 (Version 5.01, GraphPad Software, Inc., USA). Results: Assessment using recombinant enzymes showed that mitragynine gave the strongest inhibitory effect on CYP2D6 with an IC 50 value of 0.45±0.33 mM, followed by CYP2C9 and CYP3A4 with IC 50 values of 9.70±4.80 and 41.32±6.74 mM respectively. Positive inhibitors appropriate for CYP2C9, CYP2D6, and CYP3A4 which are sulfaphenazole, quinidine and ketoconazole were used respectively. V max values of CYP2C9, CYP2D6 and CYP3A4 were 0.0005, 0.01155 and 0.0137 mM luciferin formed/pmol/min respectively. K m values of CYP2C9, CYP2D6, and CYP3A4 were 32.65, 56.01, and 103.30 mM respectively. Mitragynine noncompetitively inhibits CYP2C9 and CYP2D6 activities with the K i values of 61.48 and 12.86 mM respectively. On the other hand, mitragynine inhibits CYP3A4 competitively with a K i value of 379.18 mM. Conclusions: The findings of this study reveal that mitragynine might inhibit cytochrome P450 enzyme activities, specifically CYP2D6. Therefore, administration of mitragynine together with herbal or modern drugs which follow the same metabolic pathway may contribute to herb-drug interactions.Keywords
This publication has 21 references indexed in Scilit:
- The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapyInternational Journal of Drug Policy, 2010
- Inhibitory effects of kratom leaf extract (Mitragyna speciosa Korth.) on the rat gastrointestinal tractJournal of Ethnopharmacology, 2008
- Optimizing Classification of Drug-Drug Interaction Potential for CYP450 Isoenzyme Inhibition Assays in Early Drug DiscoverySLAS Discovery, 2007
- THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVEDrug Metabolism and Disposition, 2003
- Herb–Drug, Food–Drug, Nutrient–Drug, and Drug–Drug Interactions: Mechanisms Involved and Their Medical ImplicationsThe Journal of Alternative and Complementary Medicine, 2002
- Benefits, adverse effects and drug interactionsof herbal therapies with cardiovascular effectsJACC, 2002
- Pharmacokinetic interactions between herbal remedies and medicinal drugsXenobiotica, 2002
- Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systemsEuropean Journal of Pharmacology, 1996
- Antinociceptive action of mitragynine in mice: Evidence for the involvement of supraspinal opioid receptorsLife Sciences, 1996
- Psychoactive Properties of Mitragynine (Kratom)Journal of Psychoactive Drugs, 1988